These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29119912)

  • 1. The Glutamate and the Immune Systems: New Targets for the Pharmacological Treatment of OCD.
    Marazziti D; Albert U; Mucci F; Piccinni A
    Curr Med Chem; 2018; 25(41):5731-5738. PubMed ID: 29119912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune system and obsessive-compulsive disorder.
    Marazziti D; Mucci F; Fontenelle LF
    Psychoneuroendocrinology; 2018 Jul; 93():39-44. PubMed ID: 29689421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.
    Marinova Z; Chuang DM; Fineberg N
    Curr Neuropharmacol; 2017; 15(7):977-995. PubMed ID: 28322166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamatergic dysfunction--newer targets for anti-obsessional drugs.
    Bhattacharyya S; Chakraborty K
    Recent Pat CNS Drug Discov; 2007 Jan; 2(1):47-55. PubMed ID: 18221217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults.
    Grassi G; Pallanti S
    Expert Opin Pharmacother; 2018 Oct; 19(14):1541-1550. PubMed ID: 30321070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.
    Pittenger C; Krystal JH; Coric V
    NeuroRx; 2006 Jan; 3(1):69-81. PubMed ID: 16490414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications.
    Vlček P; Polák J; Brunovský M; Horáček J
    Pharmacopsychiatry; 2018 Nov; 51(6):229-242. PubMed ID: 28950396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.
    Pittenger C; Bloch MH; Williams K
    Pharmacol Ther; 2011 Dec; 132(3):314-32. PubMed ID: 21963369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder.
    Zak JP; Miller JA; Sheehan DV; Fanous BS
    J Clin Psychiatry; 1988 Aug; 49 Suppl():23-9. PubMed ID: 3045108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obsessive-compulsive disorder.
    Goodman WK; Grice DE; Lapidus KA; Coffey BJ
    Psychiatr Clin North Am; 2014 Sep; 37(3):257-67. PubMed ID: 25150561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder.
    Carlsson ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 Jan; 25(1):5-26. PubMed ID: 11263758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach.
    Grados MA; Specht MW; Sung HM; Fortune D
    Expert Opin Drug Discov; 2013 Dec; 8(12):1515-27. PubMed ID: 24147578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of animal models of obsessive-compulsive disorder: a focus on developmental, immune, endocrine and behavioral models.
    Grados M; Prazak M; Saif A; Halls A
    Expert Opin Drug Discov; 2016; 11(1):27-43. PubMed ID: 26558411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hallucinogens, serotonin and obsessive-compulsive disorder.
    Delgado PL; Moreno FA
    J Psychoactive Drugs; 1998; 30(4):359-66. PubMed ID: 9924841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Back to the Future: The Role of Infections in Psychopathology. Focus on OCD.
    Della Vecchia A; Marazziti D
    Clin Neuropsychiatry; 2022 Aug; 19(4):248-263. PubMed ID: 36101642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology.
    Korff S; Harvey BH
    Psychiatr Clin North Am; 2006 Jun; 29(2):371-90. PubMed ID: 16650714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of PANDAS and PANS: a systematic review.
    Sigra S; Hesselmark E; Bejerot S
    Neurosci Biobehav Rev; 2018 Mar; 86():51-65. PubMed ID: 29309797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder.
    Koo MS; Kim EJ; Roh D; Kim CH
    Expert Rev Neurother; 2010 Feb; 10(2):275-90. PubMed ID: 20136383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lost in translation? A critical look at the role that animal models of obsessive compulsive disorder play in current drug discovery strategies.
    Hoffman KL; Cano-Ramírez H
    Expert Opin Drug Discov; 2018 Mar; 13(3):211-220. PubMed ID: 29275640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.